Are you a patient?

Now recommended by NICE


Act now to change the course of HF in your patients with reduced ejection fraction.

ENTRESTO was studied in PARADIGM-HF, the largest ever HF trial 1

You may know ENTRESTO by its trial name, LCZ696.

ENTRESTO was compared head to head vs the current standard of care (enalapril) in a double-blind randomised controlled trial including >8400 HF patients with reduced ejection fraction and NYHA class II-IV. 1

The trial was stopped early due to a clear benefit (median follow-up: 27 months). 1

ENTRESTO is a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker. It is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

Mode of Action

Find out more about the novel mode of action of ENTRESTO.


Understand how ENTRESTO can improve outcomes for your HF patients with reduced ejection fraction.

ARNI = angiotensin receptor–neprilysin inhibitor; ACEi = angiotensin-converting enzyme inhibitor


  1. McMurray JJV, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371(11):993–1004.
  2. ENTRESTO Summary of Product Characteristics.
  3. British Heart Foundation, 2015. Treating heart failure patients in the community with intravenous diuretics. Available at: [accessed November 2015].
  4. British Heart Foundation, 2002. Coronary Heart Disease statistics: Heart Failure Supplement. Available at: [accessed October 2015].
  5. NICE Clinical Guideline 108, Chronic Heart Failure. August 2010. Available at: [accessed November 2015].
  6. Health & Social Care Information Centre. CCG Outcomes Indicator Set England, June 2015: Quarterly publication. Available at: [accessed November 2015].
  7. Office of National Statistics, 2012. Summary: Cancer Survival in England: Patients Diagnosed, 2006-2010 and Followed up to 2011. Available at: [accessed November 2015].

Date of preparation: August 2016 ENT16-C022b(1)